Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433714 | 0.90 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL29838840 | 0.90 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL13589979 | 0.90 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL1058665 | 0.90 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL14493662 | 0.90 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL1788313 | 0.82 | POLB (0.66) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL23406968 | 0.81 | POLB (0.64) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL6858925 | 0.81 | POLB (0.46) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL5811871 | 0.81 | POLB (0.69) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL7588383 | 0.81 | POLB (0.64) | POLBALDH1A1TSHRGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803170-B2 | MIXTURE CONTAINING ACID GENERATOR | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. (JP) | 2004-10-12 | — | — | US | claimed |
| EP-1179749-B1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TEC (JP) | 2003-10-08 | — | — | EP | claimed |
| US-20020022193-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. | 2002-02-21 | — | — | US | claimed |
| EP-1179749-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | Semiconductor Leading Edge Technologies, Inc. (JP) | 2002-02-13 | — | — | EP | claimed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-6803170-B2 | MIXTURE CONTAINING ACID GENERATOR | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. (JP) | 2004-10-12 | — | — | US | disclosed |
| EP-1179749-B1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TEC (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20020022193-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | SEMICONDUCTOR LEADING EDGE TECHNOLOGIES, INC. | 2002-02-21 | — | — | US | disclosed |
| EP-1179749-A1 | Resist composition and method for manufacturing semiconductor device using the resist composition | Semiconductor Leading Edge Technologies, Inc. (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | POLB 3975/4885ALDH1A1 1391/4885TSHR 2399/4885 |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | POLB 3975/4885ALDH1A1 1391/4885TSHR 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.